메뉴 건너뛰기




Volumn 51, Issue 8, 2010, Pages 1485-1493

Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients

Author keywords

Chronic lymphocytic leukemia; rituximab; small lymphocytic lymphoma; subcutaneous cladribine

Indexed keywords

CHLORPHENIRAMINE; CLADRIBINE; HYDROCORTISONE; RITUXIMAB; STEROID;

EID: 77955449996     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.495799     Document Type: Article
Times cited : (11)

References (35)
  • 1
    • 0036273331 scopus 로고    scopus 로고
    • Alkylating agents and nucleoside analogs in the treatment of B-cell chronic lymphocityc leukemia
    • Robak T, Kasznicki M. Alkylating agents and nucleoside analogs in the treatment of B-cell chronic lymphocityc leukemia. Leukemia 2002;16:1015-1027.
    • (2002) Leukemia , vol.16 , pp. 1015-1027
    • Robak, T.1    Kasznicki, M.2
  • 2
    • 0034649696 scopus 로고    scopus 로고
    • Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
    • Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-1757.
    • (2000) N Engl J Med , vol.343 , pp. 1750-1757
    • Rai, K.R.1    Peterson, B.L.2    Appelbaum, F.R.3
  • 3
    • 51649093353 scopus 로고    scopus 로고
    • Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
    • Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-980.
    • (2008) Blood , vol.112 , pp. 975-980
    • Tam, C.S.1    O'Brien, S.2    Wierda, W.3
  • 4
    • 0031670669 scopus 로고    scopus 로고
    • Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: a report of 979 patients
    • Cheson BD Sorensen JM Vena DA et al.Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: a report of 979 patients.J Clin Oncol.1998:16:3007-3015
    • (1998) J Clin Oncol , vol.16 , pp. 3007-3015
    • Cheson, B.D.1    Sorensen, J.M.2    Vena, D.A.3
  • 5
    • 4444288930 scopus 로고    scopus 로고
    • An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine
    • Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476-1481.
    • (2004) Leukemia , vol.18 , pp. 1476-1481
    • Jehn, U.1    Bartl, R.2    Dietzfelbinger, H.3    Haferlach, T.4    Heinemann, V.5
  • 6
    • 22044444135 scopus 로고    scopus 로고
    • Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience
    • Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005;106:241-246.
    • (2005) Blood , vol.106 , pp. 241-246
    • Chadha, P.1    Rademaker, A.W.2    Mendiratta, P.3
  • 7
    • 0034063889 scopus 로고    scopus 로고
    • Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia - updated results of the multicentre study of 378 patients
    • Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia - updated results of the multicentre study of 378 patients. Br J Haematol 2000;108:357-368.
    • (2000) Br J Haematol , vol.108 , pp. 357-368
    • Robak, T.1    Bloński, J.Z.2    Kasznicki, M.3
  • 8
    • 0034667537 scopus 로고    scopus 로고
    • Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial
    • Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96:2723-2729.
    • (2000) Blood , vol.96 , pp. 2723-2729
    • Robak, T.1    Bloński, J.Z.2    Kasznicki, M.3
  • 9
    • 77955448467 scopus 로고    scopus 로고
    • Randomized comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy in chronic lymphocytic leukaemia: Updated results of PALGCLL3 trial
    • Robak T, Blonski JZ, Gora-Tybor J, et al. Randomized comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy in chronic lymphocytic leukaemia: updated results of PALGCLL3 trial. Leuk Lymphoma 2007;48(Suppl.): 162.
    • (2007) Leuk Lymphoma , vol.48 , Issue.SUPPL. , pp. 162
    • Robak, T.1    Blonski, J.Z.2    Gora-Tybor, J.3
  • 10
    • 72149085331 scopus 로고    scopus 로고
    • Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukaemia (CLL). First results from the International Randomized Phase III trial
    • (Abstract 630)
    • Karlsson KA, Strömberg M, Jönsson V, Mulligan SP, Liliemark J, Juliusson G. Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukaemia (CLL). First results from the International Randomized Phase III trial. Blood 2007;110(Suppl. 1):194a (Abstract 630).
    • (2007) Blood , vol.110 , Issue.SUPPL. 1
    • Karlsson, K.A.1    Strömberg, M.2    Jönsson, V.3    Mulligan, S.P.4    Liliemark, J.5    Juliusson, G.6
  • 11
    • 0037108822 scopus 로고    scopus 로고
    • Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma
    • Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;15: 4261-4267.
    • (2002) J Clin Oncol , vol.15 , pp. 4261-4267
    • Hainsworth, J.D.1    Litchy, S.2    Burris III, H.A.3
  • 12
    • 0034796371 scopus 로고    scopus 로고
    • Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity to either drug alone
    • Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity to either drug alone. Br J Haematol 2001;114:800-809.
    • (2001) Br J Haematol , vol.114 , pp. 800-809
    • Di Gaetano, N.1    Xiao, Y.2    Erba, E.3
  • 13
    • 19944429446 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine may prolong progression free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: in an updated retrospective analysis of CALGB 9712 and CALGB 9011
    • Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: in an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105:49-53.
    • (2005) Blood , vol.105 , pp. 49-53
    • Byrd, J.C.1    Rai, K.2    Peterson, B.L.3
  • 14
    • 33749600951 scopus 로고    scopus 로고
    • Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma
    • Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski JZ. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006;107:1542-1550.
    • (2006) Cancer , vol.107 , pp. 1542-1550
    • Robak, T.1    Smolewski, P.2    Cebula, B.3    Szmigielska-Kaplon, A.4    Chojnowski, K.5    Blonski, J.Z.6
  • 15
    • 58149331063 scopus 로고    scopus 로고
    • Expression of the human concentrative nucleotide transporter (hCNT1) gene correlates with clinical response in patients affected by Waldenstrom's macroglobulinemia (WM), undergoing a combination treatment with cladribine (2-CdA) and rituximab
    • (Abstract 1357)
    • Laszlo D, Rabascio C, Andreola G, et al. Expression of the human concentrative nucleotide transporter (hCNT1) gene correlates with clinical response in patients affected by Waldenstrom's macroglobulinemia (WM), undergoing a combination treatment with cladribine (2-CdA) and rituximab. Blood 2007;110(Suppl. 1):408a (Abstract 1357).
    • (2007) Blood , vol.110 , Issue.SUPPL. 1
    • Laszlo, D.1    Rabascio, C.2    Andreola, G.3
  • 16
    • 0029981025 scopus 로고    scopus 로고
    • National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
    • Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
    • (1996) Blood , vol.87 , pp. 4990-4997
    • Cheson, B.D.1    Bennett, J.M.2    Grever, M.3
  • 18
    • 0037406968 scopus 로고    scopus 로고
    • ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia
    • Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia. N Eng J Med 2003;348:1764- 1775.
    • (2003) N Eng J Med , vol.348 , pp. 1764-1775
    • Crespo, M.1    Bosch, F.2    Villamor, N.3
  • 19
    • 34247594390 scopus 로고    scopus 로고
    • International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukemia
    • Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukemia. Leukemia 2007;21:956-964.
    • (2007) Leukemia , vol.21 , pp. 956-964
    • Rawstron, A.C.1    Villamor, N.2    Ritgen, M.3
  • 20
    • 45149100665 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: Aa report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute- Working Group 1996 guidelines
    • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood 2008;111:5446-5456.
    • (2008) Blood , vol.111 , pp. 5446-5456
    • Hallek, M.1    Cheson, B.D.2    Catovsky, D.3
  • 21
    • 61849091076 scopus 로고    scopus 로고
    • Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and R (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL)
    • (Abstract 325)
    • Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and R (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl. 1):125 (Abstract 325).
    • (2008) Blood , vol.112 , Issue.SUPPL. 1 , pp. 125
    • Hallek, M.1    Fingerle-Rowson, G.2    Fink, A.M.3
  • 22
    • 62549117867 scopus 로고    scopus 로고
    • Preliminary results of the combination rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) followed by rituximab maintenance in prevously untreated chronic lymphocytic leukemia (CLL)
    • (Abstract 626)
    • Bosch F, Muntanola A, Villamor N, et al. Preliminary results of the combination rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) followed by rituximab maintenance in prevously untreated chronic lymphocytic leukemia (CLL). Blood 2007;110(Suppl. 1):193a (Abstract 626).
    • (2007) Blood , vol.110 , Issue.SUPPL. 1
    • Bosch, F.1    Muntanola, A.2    Villamor, N.3
  • 23
    • 0026347961 scopus 로고
    • 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia
    • Saven A, Carrera CJ, Carson DA, et al. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 1991;5(Suppl. 1):133-138.
    • (1991) Leuk Lymphoma , vol.5 , Issue.SUPPL. 1 , pp. 133-138
    • Saven, A.1    Carrera, C.J.2    Carson, D.A.3
  • 24
    • 0027465143 scopus 로고
    • High complete remission rate from 2-chlordeoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease in blood lymphocyte count
    • Juliusson G, Liliemark J. High complete remission rate from 2-chlordeoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease in blood lymphocyte count. J Clin Oncol 1993;11:679-689.
    • (1993) J Clin Oncol , vol.11 , pp. 679-689
    • Juliusson, G.1    Liliemark, J.2
  • 25
    • 0030018146 scopus 로고    scopus 로고
    • Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia
    • Juliusson G, Liliemark J. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol 1996;7:373-379.
    • (1996) Ann Oncol , vol.7 , pp. 373-379
    • Juliusson, G.1    Liliemark, J.2
  • 26
    • 0028945716 scopus 로고
    • 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia
    • Saven A, Lemon RH, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995;13:570-574.
    • (1995) J Clin Oncol , vol.13 , pp. 570-574
    • Saven, A.1    Lemon, R.H.2    Kosty, M.3
  • 27
    • 1842588045 scopus 로고    scopus 로고
    • Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies
    • Robak T, Smolewski P, Urbanska-Rys H, Gora-Tybor J, Blonski JZ, Kasznicki M. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma 2004;45:937-944.
    • (2004) Leuk Lymphoma , vol.45 , pp. 937-944
    • Robak, T.1    Smolewski, P.2    Urbanska-Rys, H.3    Gora-Tybor, J.4    Blonski, J.Z.5    Kasznicki, M.6
  • 28
    • 0029956950 scopus 로고    scopus 로고
    • Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia
    • Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996;14:2160-2166.
    • (1996) J Clin Oncol , vol.14 , pp. 2160-2166
    • Juliusson, G.1    Christiansen, I.2    Hansen, M.M.3
  • 29
    • 0027056958 scopus 로고
    • On the bioavailability of oral and subcutaneous 2-chloro-20- deoxyadenosine in humans: Alternative routes of administration
    • Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-20-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992;10:1514-1518.
    • (1992) J Clin Oncol , vol.10 , pp. 1514-1518
    • Liliemark, J.1    Albertioni, F.2    Hassan, M.3    Juliusson, G.4
  • 30
    • 7344254620 scopus 로고    scopus 로고
    • Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukemia
    • Betticher DC, Ratschiller D, Hsu Schmitz S-F, et al. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukemia. Ann Oncol 1998;9:721-726.
    • (1998) Ann Oncol , vol.9 , pp. 721-726
    • Betticher, D.C.1    Ratschiller, D.2    Hsu Schmitz, S.-F.3
  • 31
    • 33846258434 scopus 로고    scopus 로고
    • Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    • Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405-411.
    • (2007) Blood , vol.109 , pp. 405-411
    • Kay, N.E.1    Geyer, S.M.2    Call, T.G.3
  • 32
    • 0037220152 scopus 로고    scopus 로고
    • Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patientswith B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712)
    • Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patientswith B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14.
    • (2003) Blood , vol.101 , pp. 6-14
    • Byrd, J.C.1    Peterson, B.L.2    Morrison, V.A.3
  • 33
    • 59149106873 scopus 로고    scopus 로고
    • Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: Molecular remissions predict for durable complete responses
    • Lamanna N, Jurcic JG, Noy A, et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009; 27:491-497.
    • (2009) J Clin Oncol , vol.27 , pp. 491-497
    • Lamanna, N.1    Jurcic, J.G.2    Noy, A.3
  • 34
    • 78650542873 scopus 로고    scopus 로고
    • Impact of different chemotherapy regimen in comorbid patients with advanced chronic lymphocytic leukemia: Metaanalysis of two phase-III trials of the German CLL Study Group
    • (Abstract 2840)
    • Cramer P, Goede V, Jenke P, Busch R, Hallek M, Eichhorst B. Impact of different chemotherapy regimen in comorbid patients with advanced chronic lymphocytic leukemia: metaanalysis of two phase-III trials of the German CLL Study Group. Blood 2006;108(Suppl. 1):804a (Abstract 2840).
    • (2006) Blood , vol.108 , Issue.SUPPL. 1 , pp. 804
    • Cramer, P.1    Goede, V.2    Jenke, P.3    Busch, R.4    Hallek, M.5    Eichhorst, B.6
  • 35
    • 0028987180 scopus 로고
    • P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
    • Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85: 1580-1589.
    • (1995) Blood , vol.85 , pp. 1580-1589
    • Döhner, H.1    Fischer, K.2    Bentz, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.